ArticleScientific reports2025
Characterization of genetic mutations in hepatitis B virus isolated from HBsAg+/HBcAb+/HBsAb-/HBV DNA + Japanese blood donors.
Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Cytokine gene polymorphisms and susceptibility to chronic hepatitis B virus infection in familial clusters from Iran: a cross-sectional study.BMC infectious diseases · 2026Article
- Dysfunction of circulating follicular helper T cells in people living with HIV who are HBV small surface protein antibody (HBsAb)-negative despite HBV vaccination.BMC infectious diseases · 2026Article
- Hepatitis B vaccination in Chinese infants (2002-2006, Guangdong): long-term effectiveness in adulthood and biological features of HBV infection.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In Japan, a universal hepatitis B (HB) vaccination was introduced in 2016. Through continuous analysis of HBV DNA mutations, the changes in HBV prevalence before and after the introduction of the universal HB vaccine can be monitored. In this study, we conducted mutational analysis of HBV DNA in HB small protein antigen-positive/HBV core antibody-positive/HB small protein antibody-positive/HBV DNA-positive donor blood samples, with the aim of establishing a baseline prior to the introduction of universal vaccination. We successfully sequenced the full-length HBV DNA in 32 of 33 samples. Immune-escape mutations in the S protein were frequently detected in genotypes B and C. In genotype B, a 1896 nonsense mutation in the precore protein-coding region, which enhances HBV replication and is associated with HB e antigen negativity, was detected at high frequency. In genotype A, the 1858 mutation, which suppresses the 1896 nonsense mutation, was detected at a high frequency. The 1762/1764 double mutation, a risk factor for hepatocellular carcinoma (HCC), was detected frequently in genotype C. These findings provide baseline data and indicate the need for continued monitoring to assess whether universal vaccination influences mutation patterns over time.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.